S John Weroha
Overview
Explore the profile of S John Weroha including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
2336
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Norman A, Seetharam M, Allred J, Kong J, Opyrchal M, Ma W, et al.
BJC Rep
. 2025 Jan;
3(1):1.
PMID: 39809926
Background: Based on preclinical data showing addition of CDK4/6 inhibitors to gemcitabine was synergistic, ribociclib was evaluated in combination with gemcitabine to determine the maximum tolerated dose (MTD) and dose...
2.
Caggiano R, Prokhorova E, Duma L, Schutzenhofer K, Lauro R, Catara G, et al.
Neoplasia
. 2024 Nov;
59:101092.
PMID: 39615107
The ADP-ribosyl hydrolases PARG and ARH3 counteract PARP enzymatic activity by removing ADP-ribosylation. PARG and ARH3 activities have a synthetic lethal effect; however, the specific molecular mechanisms underlying this response...
3.
Venkatachalam A, Correia C, Peterson K, Hou X, Schneider P, Strathman A, et al.
Mol Cancer
. 2024 Oct;
23(1):224.
PMID: 39375715
Recent studies indicate that replication checkpoint modulators (RCMs) such as inhibitors of CHK1, ATR, and WEE1 have promising monotherapy activity in solid tumors, including platinum-resistant high grade serous ovarian cancer...
4.
Taya M, Hou X, Veneris J, Kazi N, Larson M, Maurer M, et al.
J Gynecol Oncol
. 2024 Jun;
36(1):e4.
PMID: 38909640
Objective: In ovarian cancer (OvCa), tumor cell high glucocorticoid receptor (GR) has been associated with poor patient prognosis. In vitro, GR activation inhibits chemotherapy-induced OvCa cell death in association with...
5.
Rodman E, Emch M, Hou X, Bajaj A, Pearson N, John A, et al.
bioRxiv
. 2024 Jun;
PMID: 38895264
Statement Of Significance: Lestaurtinib is a novel inhibitor of ovarian cancer, including chemotherapy- and PARPi-resistant models, that acts through robust inhibition of the JAK/STAT pathway and synergizes with standard-of-care agents...
6.
Kalogera E, Nevala W, Finnes H, Suman V, Schimke J, Strand C, et al.
Clin Cancer Res
. 2024 Mar;
30(12):2623-2635.
PMID: 38530846
Purpose: AB160 is a 160-nm nano-immunoconjugate consisting of nab-paclitaxel (ABX) nanoparticles noncovalently coated with bevacizumab (BEV) for targeted delivery into tissues expressing high levels of VEGF. Preclinical data showed that...
7.
Shafa A, Watkins A, McGree M, Weroha S, Wahner Hendrickson A, Block M, et al.
Gynecol Oncol
. 2023 Jul;
176:36-42.
PMID: 37442024
Objectives: Our objectives were to determine the incidence, timing, and risk factors for venous thromboembolisms (VTEs) in patients with advanced stage epithelial ovarian cancer (EOC) who received neoadjuvant chemotherapy (NACT)....
8.
Sandoval L, Mohammed Ismail W, Mazzone A, Dumbrava M, Fernandez J, Munankarmy A, et al.
Genes (Basel)
. 2023 Jun;
14(6).
PMID: 37372428
The snATAC + snRNA platform allows epigenomic profiling of open chromatin and gene expression with single-cell resolution. The most critical assay step is to isolate high-quality nuclei to proceed with...
9.
Gonzalez-Bosquet J, Weroha S, Bakkum-Gamez J, Weaver A, McGree M, Dowdy S, et al.
Front Oncol
. 2023 Jun;
13:1105504.
PMID: 37287928
Objective: To identify high-risk disease in clinicopathologic low-risk endometrial cancer (EC) with high microsatellite instability (MSI-H) or no specific molecular profile (NSMP) and therapeutic insensitivity in clinicopathologic high-risk MSI-H/NSMP EC....
10.
Hu C, Nagaraj A, Shimelis H, Montalban G, Lee K, Huang H, et al.
Cancer Res
. 2023 May;
83(15):2557-2571.
PMID: 37253112
Significance: Functional analysis of the impact of a large number of missense variants on RAD51C function provides insight into RAD51C activity and information for classification of the cancer relevance of...